Category > Prostate Cancer

New Pathway to Potential Therapies for Advanced Prostate Cancer

» 27 July 2011 » In Castration Resistant, Clinical trials, Hormone refractory, Metastatic, Prostate Cancer » Comments Off

Dr. Nima Sharifi

Dr. Nima Sharifi

PSA Rising /DALLAS/ – July 25, 2011 – UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than previously was thought.

“We have recently discovered that castration resistant prostate cancer (CRPC) is unexpectedly driven by dihydrotestosterone synthesis from adrenal precursors in a pathway that circumvents testosterone,” says Dr. Nima Sharifi, assistant professor of internal medicine and senior author of a  study in Proceedings of the National Academy of Sciences.

“The dominant pathway to DHT synthesis from adrenal precursors in CRPC [castration resistant prostate cancer] follows an alternative route that bypasses T and requires steroid 5α-reductase isoenzyme-1 (SRD5A1),” Dr. Sharifi writes.

Continue reading...

Tags: , , ,

Provenge available for men with advanced prostate cancer at Roswell Park

» 15 February 2011 » In Hormone refractory, Immunotherapy, Metastatic, PCa Treatments, Prostate Cancer, Provenge, Vaccines » Comments Off

February 7 2011, BUFFALO, NY — The nation’s first FDA-approved cancer treatment vaccine, Provenge (sipuleucel-T), is being offered for the first time in Western New York at Roswell Park Cancer Institute (RPCI). The vaccine is designed for men with advanced prostate cancer who have limited treatment options and who meet eligibility requirements.

Continue reading...

Tags: , , ,

How does a robotic prostatectomy work?

» 15 February 2011 » In Laparoscopic surgery, Prostate Cancer, Radical Prostatectomy, Robotic surgery » Comments Off

Robot assisted prostate surgery, known medically as the da Vinci prostatectomy, has had a profound influence over treatment during the past decade. Robotic surgical technology was first developed by the military for use in the battlefield. However during the past decade, this technology has been rapidly applied to the general medical setting, notably in the field of prostate cancer.

Continue reading...

Tags: , ,

Dendreon Sets Provenge Price at $93,000 – Only 2,000 Patients Will Get it in First Year

» 29 April 2010 » In Dendreon, Prostate Cancer, Provenge, Vaccines » Comments Off

Dendreon is pricing Provenge high and for the first year its availability will be low, according to a report today in Xconomy, a Seattle business website. Provenge, the first immunotherapy to win FDA approval for treatment of men with prostate cancer, will cost $93,000 per patient. Only 2,000 patients will be treated with Provenge in the first year.

Continue reading...

FDA Approves PROVENGE ® for the Treatment of Men with Advanced Prostate Cancer

» 29 April 2010 » In Cancer, FDA, Prostate Cancer, Provenge, Vaccines » Comments Off

SEATTLE, April 29, 2010 –Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(®) (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). Provenge is designed to induce an immune response against Prostatic Acid Phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.

Continue reading...

Phase 3 Trial Underway for MDV 3100 for Advanced Prostate Cancer

» 15 April 2010 » In Cancer, Clinical trials, MDV 3100, Metastatic, Prostate Cancer, trial results » Comments Off

In light of favorable results from the Phase 1-2 trial of MDV 3100 for advanced prostate cancer, a Phase 3 trial is enrolling at sites in the US, Canada, South America, UK, Europe, Australia, and South Africa. Results from the earlier trial are published online by the UK medical journal The Lancet.

Continue reading...

Provenge Trial Ongoing & Recruiting At Eight US Centers

» 25 November 2009 » In Clinical trials, Dendreon, Prostate Cancer, Provenge, Vaccines » Comments Off

An open-label study of Sipuleucel-T (Provenge) is ongoing at 8 centers across the USA. This is a Phase 2 Study enrolling men with Metastatic Castrate Resistant Prostate Cancer (CRPC).

The aim of this study is to measure the immune responses to treatment with sipuleucel-T (Provenge). All participants will receive the drug.

Continue reading...

Tags: , , ,

Obesity as a Factor in Prostate Cancer Treatment Options

» 06 November 2009 » In PCa Treatments, Prostate Cancer, Robotic surgery » Comments Off

BY DOUGLAS SCHERR M.D.

Dr. Douglas Scherr, MD

Dr. Douglas Scherr, MD

Obesity is becoming an increasing concern with regard to prostate cancer treatment decisions as the number of patients with a Body Mass Index (BMI) of greater than 30 grows. While there hasn’t been conclusive study into the area, it has been generally found that obesity is a negative risk factor for prostate cancer.

Continue reading...

Tags: , , , , ,

Free Prostate Screening in Seattle November 20

» 05 November 2009 » In Prostate Cancer » Comments Off

Seattle Prostate Institute, an affiliate of Swedish Cancer Institute, is offering free prostate cancer screening tests on Fri., Nov. 20 between 8 a.m. and 3:30 p.m. at their offices in the 1101 Madison Medical Tower, Suite 1101, on the Swedish/First Hill Campus.

Continue reading...

ASTRO Prostate Cancer News Headlines Preview

» 31 October 2009 » In Beam Radiation, PCa Treatments, Prostate Cancer, Proton » Comments Off

The American Society for Radiation Oncology (ASTRO) will host news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting to be held this coming week in Chicago. Prostate cancer features in three of briefings. Here are the headlines:

Continue reading...

Tags:

Page 1 of 1512345...14Last »»